Clinical trial
Applied Database Study of Oculomotor-Pupillary Biomarkers Using Edge AI for Clinical Evaluation and Prediction in Parkinson's Disease
NCT07886450 is registered in ClinicalTrials.gov with The Hong Kong Polytechnic University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Applied Database Study of Oculomotor-Pupillary Biomarkers Using Edge AI for Clinical Evaluation and Prediction in Parkinson's Disease
- Lead sponsor
- The Hong Kong Polytechnic University
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- November 1, 2026
- Completion date
- December 31, 2027
- Enrollment
- 128 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
parkinson disease (disorder)
Arms
As registered; 2 arms.
-
Parkinson's Disease Group
-
Healthy Control Group
Primary endpoints
Registered primary outcome measures; 3 primary.
-
Differences in mean prosaccade gain between early-to-moderate PD patients and healthy controls.
Prosaccade gain is defined as the ratio of the primary saccade amplitude to the target displacement amplitude, measured using a head-mounted infrared eye-tracking device. The mean gain across valid trials will be calculated for each participant. Mean prosaccade gain will be compared between patients with early-to-moderate PD and healthy controls.
-
Differences in antisaccade directional error rate between early-to-moderate PD patients and healthy controls.
Antisaccade directional error rate is defined as the percentage of valid antisaccade trials in which the initial saccade is incorrectly directed toward the visual target rather than in the opposite direction, measured using a head-mounted infrared eye-tracking device. The error rate will be calculated for each participant as the number of directional error trials divided by the total number of valid antisaccade trials, multiplied by 100. Antisaccade directional error rate will be compared between patients with early-to-moderate PD and healthy controls.
-
Differences in mean prosaccade peak velocity between early-to-moderate PD patients and healthy controls.
Prosaccade peak velocity is defined as the maximum angular eye velocity during the primary prosaccade, measured in degrees per second (°/s) using a head-mounted infrared eye-tracking device. The mean peak velocity across valid trials will be calculated for each participant. Mean prosaccade peak velocity will be compared between patients with early-to-moderate PD and healthy controls.
Lead sponsor's other trials
The Hong Kong Polytechnic University, most recent start first.
+675 more trials
Similar trials
Same condition (Parkinson Disease) and phase, most recent start first.
+1,091 more trials See the condition page